DexCom, Inc. $DXCM Stock Position Decreased by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 129,788 shares of the medical device company’s stock after selling 7,504 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in DexCom were worth $8,714,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of DXCM. Brighton Jones LLC grew its holdings in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC lifted its holdings in shares of DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares during the last quarter. Empowered Funds LLC boosted its position in DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares during the period. Focus Partners Wealth grew its stake in DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after buying an additional 841 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its position in DexCom by 18.7% in the second quarter. Farther Finance Advisors LLC now owns 3,680 shares of the medical device company’s stock worth $321,000 after buying an additional 580 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 0.7%

Shares of NASDAQ:DXCM opened at $73.34 on Tuesday. The company has a 50 day moving average of $66.71 and a 200-day moving average of $70.98. The firm has a market cap of $28.60 billion, a P/E ratio of 40.74, a P/E/G ratio of 1.31 and a beta of 1.48. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the business earned $0.45 earnings per share. The business’s revenue for the quarter was up 21.6% on a year-over-year basis. As a group, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the transaction, the director owned 27,031 shares of the company’s stock, valued at $1,569,690.17. This trade represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Jacob Steven Leach purchased 18,200 shares of the company’s stock in a transaction on Monday, November 10th. The stock was acquired at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer owned 331,697 shares of the company’s stock, valued at $18,256,602.88. This represents a 5.81% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have sold 7,866 shares of company stock worth $448,177. 0.32% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

DXCM has been the subject of several analyst reports. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. JPMorgan Chase & Co. decreased their target price on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Friday, October 31st. Citigroup restated a “buy” rating and issued a $77.00 price target (up previously from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Canaccord Genuity Group set a $99.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, TD Cowen decreased their price objective on DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $86.30.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.